CareDx, Inc (CDNA)
$
13.11
-0.18 (-1.37%)
Key metrics
Financial statements
Free cash flow per share
0.3286
Market cap
707.4 Million
Price to sales ratio
2.0755
Debt to equity
0.0696
Current ratio
3.2979
Income quality
0.3429
Average inventory
25.4 Million
ROE
0.1522
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
CareDx, Inc. is dedicated to discovering, developing, and commercializing diagnostic solutions tailored for transplant patients and their caregivers globally. The company operates several innovative products, such as AlloSure Kidney, which utilizes donor-derived cell-free DNA (dd-cfDNA) for kidney transplant patients, and AlloMap Heart, a gene expression solution for heart transplant recipients. Additionally, it provides AlloSure Heart and AlloSure Lung, both dd-cfDNA solutions for heart and lung transplant patients, respectively. CareDx also introduces TruSight HLA, which is a next generation sequencing (NGS) based high-resolution typing solution, alongside Olerup SSP for typing human leukocyte antigen (HLA) alleles through sequence-specific primer technology. Other offerings include QTYPE for precise HLA typing, Ottr for transplant patient management, AlloSeq Tx for high-resolution HLA typing, AlloSeq cfDNA for blood surveillance of dd-cfDNA, AlloSeq HCT for chimerism testing in stem cell transplant recipients, and XynQAPI for transplant quality tracking. The company also offers AlloCare, a mobile app aimed at providing patient-centric resources for transplant recipients. CareDx markets its products directly to customers and utilizes third-party distributors and sub-distributors. The company has secured a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products, and with Cibiltech SAS to commercialize iBox, a predictive analysis software for post-transplantation kidney allograft loss. The company incurred an income tax expense of $310,000.00 indicating its tax obligations. It recorded a notable revenue of $333,785,000.00 showcasing its steady growth. Additionally, CareDx reported depreciation and amortization expenses of $19,757,000.00 reflecting the wear and tear of its assets, while the net total of other income and expenses is $12,094,000.00 reflecting non-core financial activities. Finally, the company incurred an interest expense of $0.00 reflecting its debt servicing obligations. The stock of CareDx is affordable at $20.02 making it a suitable option for budget-conscious investors. The stock has an average trading volume of 1,528,096.00 indicating moderate liquidity, which could attract interest from various investors. With a market capitalization of $697,804,659.00 the company is classified as a small-cap player, offering unique investment opportunities within the market. CareDx is recognized as a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative products and solutions. Furthermore, it belongs to the Healthcare sector, where it drives innovation and growth, establishing its pivotal role in the advancement of transplant diagnostics and patient care.
Is CareDx, Inc (CDNA) a good investment?
Investing in CareDx, Inc (CDNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is CareDx, Inc (CDNA)'s stock forecast?
Analysts predict CareDx, Inc stock to fluctuate between $10.96 (low) and $32.97 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is CareDx, Inc's market capitalization?
As of 2025-08-29, CareDx, Inc's market cap is $697,804,659, based on 53,226,900 outstanding shares.
How does CareDx, Inc compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., CareDx, Inc has a Lower Market-Cap, indicating a difference in performance.
How can I buy CareDx, Inc (CDNA) stock?
To buy CareDx, Inc (CDNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CDNA. Place an order (Market, Limit, etc.).
What is the best time to invest in CareDx, Inc?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did CareDx, Inc perform in the last earnings report?
Revenue: $333,785,000 | EPS: $1 | Growth: -128.25%.
Where can I find CareDx, Inc's investor relations reports?
Visit https://www.caredx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for CareDx, Inc?
You can explore historical data from here
What is the all-time high and low for CareDx, Inc stock?
All-time high: $84.94 (2021-08-06) | All-time low: $4.80 (2023-10-27).
What are the key trends affecting CareDx, Inc stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
benzinga.com
CareDx, Inc. CDNA faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company's expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.
seekingalpha.com
CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.
zacks.com
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.
businesswire.com
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Tim.
seekingalpha.com
CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and operational improvements have strengthened the investment case, yet the company has never achieved operating profitability, raising concerns. Future growth depends on successful new product launches and expanding its ecosystem, but ongoing innovation is required to stay ahead of AI-driven competitors.
businesswire.com
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seven.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certain CareDx insiders caused the company to issue false and misleading public statements regarding its compliance with health.
globenewswire.com
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.
See all news
